

Dutch Life Sciences Conference **Impact Investing**

Eleanor Price

WE TRANSLATE INNOVATION TO IMPACT - DELIVERING SUPERIOR RETURNS

THUJA CAPITAL KEY FIGURES



HQUtrecht
The Netherlands



AUM €130M 3 funds



Latest fund TCHF III 2020 vintage

- Investment team of highly experienced PhDs and MDs
- + Strong network of universities and knowledge partners
- Active investor with hands-on approach to delivering value



Early stageSeed &
Series A



Technology focus
BioPharma &
MedTech



Europe focus Benelux & Germany



Thuja's investment strategy strongly aligns with the UNs SDGs









































We invest in innovations aiming to achieve ≥1 of our impact goals

Thuja's impact goals



Live longer
Reduce pre-mature death
due to disease



Live better
Improve quality of life




Reduce costs

Deliver savings to the healthcare system



Healthcare impact is not typically realised within the holding period


Typical timeline of a medical innovation





Impact potential versus realised impact








We assess healthcare impact potential

Typical timeline of a medical innovation





Assessing healthcare impact potential



Thuja's Healthcare Impact Framework



Outcome indicators

Intended use of the innovation

Expected improvement over SoC

Moderating indicators

Prevalence

Access

Impact indicators

Live longer

Live better

Reduce healthcare costs

Improve treatment

Major improvement (5)

<0.25% population (2)

Fair (3)



Major (5) impact on life expectancy



Large (4) impact on QoL



No expected impact on costs



Ecosystem impact is realized within the holding period

Typical timeline of a medical innovation


🚐 We measure the additional impact realised We assess the due to our early investment and active healthcare impact portfolio management potential of all prospective investments Healthcare Healthcare impact 2-4 years **5-10** years 1-3 years impact realised potential New **Pre-clinical** Market **Product to** Clinical development idea/concept development patient access The holding period Typical period in which the company is in Thuja's portfolio



Assessing ecosystem impact



Thuja's impact roadmap



Impact committee

Goal progress is assessed by our independent impact committee



Annelien van Meer



Maarten Holtslag



Julia Samson





Thank you for your time!

LSI Building Yalelaan 62 3458 CM Utrecht

thujacapital.com

